Check out our wide range of fillers and injectables.
No products were found matching your selection.
Monovisc is an orthopedic injectable composed of non-animal sodium hyaluronate that is used to bring pain relief to patients afflicted with osteoarthritis of the knee. This product is manufactured by Anika Therapeutics.
The ingredients of Monovisc provide patients’ joints with the mechanical support they need, as well as additional joint lubrication to reduce the pain associated with osteoarthritis. Monovisc assumes the form of a viscous gel that has physical properties similar to that of healthy synovial fluid found in the articular joint. This product is injected to restore the natural rheological environment of the joint, resulting in reduced joint damage, lowered inflammation and the relief of symptoms.
This single-dose treatment ensures that the patient gains all the benefits of treatment in a single injection session. With fewer injections, the risk of infection and other procedure-related side effects is also lowered.
Treatment with Monovisc is ideal for patients who have tried analgesic treatments and exercise to improve their condition but found these modalities to be inadequate, and can be used in combination with other osteoarthritis treatments to supplement the effects.
Additionally, the hyaluronic acid that Monovisc is composed of is of non-animal origin, which aids in reducing hypersensitivity reactions.
The hyaluronic acid in this product is modified to give it the optimal biomechanical properties required to effectively treat osteoarthritis and to ensure long-lasting results (up to 6 months).
Monovisc is safe for use and is generally well-tolerated in patients that are suffering from osteoarthritis. It can be used together with other osteoarthritis treatments. That being said, certain groups of patients should be excluded from Monovisc treatment, such as patients with known allergy to any of the components of Monovisc, active inflammation or infection at the intended injection site, bleeding disorders, who are receiving anticoagulant therapy, who are prone to keloid formation or hypertrophic scarring, who are pregnant or breastfeeding, and children under 18 years of age.
The Monovisc injection procedure does not result in any downtime. Patients can resume their daily activities right after the treatment.